Answer:
Book Value per share is $2.96 and Earnings per share is $1.78
Explanation:
The market-to-book ratio is:
<u>Market Value </u> = 3.31 times
Book Value
The market value of the stock is $9.80 per share. Therefore, to calculate the Book Value, we make the Book Value subject and divide the ratio by Market Value per share:
Book Value per Share = <u>Market Value per share</u>
Market-to-Book ratio
= <u>9.80</u>
3.31
= $2.96
The PE ratio is:
<u> Price </u> = 5.51 times
Earnings
The price of the stock is $9.80 per share. Therefore, to calculate the Earnings per share, we make the Earnings subject and divide the PE ratio by Price of stock:
Earnings per share = <u> Price </u>
PE Ratio
= <u>9.80</u>
5.51
= $1.78
Answer:
Business slander
Explanation:
Business slander - it is considered to be business defamation when one party used unfair statements toward another competitive partner. This kind of statement is considered to be objectionable when parties comment or try to damage the competitor's reputation for personal interest.
Slander in business gives the right to person to file a civil action against the false statement by another person.
Answer:
C. $ 168 comma 000
Explanation:
The computation of the residual income is shown below:
= Operating income - minimum return
where,
Operating income is $600,000
And, the minimum return equal to
= Invested asset amount × minimum rate of return
= $3,600,000 × 12%
= $432,000
Now put these values to the above formula
So, the value would equal to
= $600,000 - $432,000
= $168,000
We simply applied the above formula
Answer:
Contribution margin per unit = $40
Explanation:
Provided information we have,
Selling price of unit = $100
Variable cost per unit = $60
Total monthly fixed cost = $30,000
Number of units sold = 1,000
Contribution margin per unit = ?
Therefore, we know contribution margin per unit = Selling price per unit - Variable cost per unit = $100 - $60 = $40
Therefore, contribution for total units sold = $40 
1,000 = $40,000
Final Answer
Contribution margin per unit = $40
Answer:
BrisCor
Budgeting, ethics, pharmaceutical company
a. Referring to the "Standards of Ethical Behavior for Practitioners of Management Accounting and Financial Management,"
none of the preceding items are acceptable to use.
b. I would recommend Jackson to go ahead with the R&D throughout the year to ensure that the drug Vyacon was successfully brought to the market next year before the competitor. He can try to keep to the budget going forward. A budget remains a budget and not the actual. Budget overrun can result. What is important is its effectiveness in achieving business goals.
Explanation:
The announced expectations of third-quarter earnings to Wall Street analysts should not prevent the R&D on the drug Vyacon from continuing, provided Jackson is certain that the envisaged success would be attained. They remain expectations. They are not the actual results of operations for the year. Even if the company's stock price would tumble, it would still recover after the drug had received approval and gone to market, raking in large profits. After all, the projected increase in R&D cost might not result, and the drug Vyacon could be fully developed and ready for the market before year-end, thereby not exceeding its budget.
